AllSci News
Opus Genetics secures NIH grant for LCA9 gene therapy IND-enabling studies
Opus Genetics has been awarded a USD 1.01 million National Eye Institute Small Business Innovation Research award to advance OPGx-NMNAT1, an AAV9-based gene...
J&J's Icotyde adds EU approval for plaque psoriasis.
The European Commission has approved Johnson & Johnson’s Icotyde (icotrokinra) for adults and adolescents aged 12 years and older with moderate-to-severe...
Greek startup Anacalypsis gets seed funding for non-kinase LRRK2 strategy in Parkinson’s
Greece-based Anacalypsis Therapeutics has raised a pre-seed financing round led by Metavallon VC through its Brain Gain Fund to advance AT001, a stapled...
Menarini, NewAmsterdam win EU approval for first CETP inhibitor in hypercholesterolemia
The European Commission has granted marketing authorization for obicetrapib as both a monotherapy (Ubeslo) and a fixed-dose combination with ezetimibe...
Halozyme prices upsized USD 1.3b convertible offering to extend ENHANZE's IP runway
Halozyme Therapeutics raised USD 1.3 billion through an upsized convertible senior note offering, adding capital for debt refinancing, general corporate...
Xenetic to acquire Santersus in NET-targeting biotech combination
Framingham, Massachusetts-based Xenetic Biosciences (Nasdaq: XBIO) has agreed to acquire Switzerland-based Santersus AG in an all-stock share exchange,...
Lilly wins FDA approval for Inluriyo-Verzenio breast cancer combo
The US FDA has granted full approval to Inluriyo (imlunestrant), an oral selective estrogen receptor degrader (SERD), in combination with Verzenio...
Hanx Bio licenses XtalPi AI drug discovery platform for biologics R&D
Hanx Biopharmaceuticals (Wuhan) Co., Ltd. (HKEX: 03378) and XtalPi Holdings Limited (HKEX: 02228) have entered into a Strategic Cooperation Framework...
Alkermes’ orexin agonist shows dose-dependent ADHD symptom reductions in Phase Ib study
ALKS 7290, Alkermes' (Nasdaq: ALKS) oral orexin 2 receptor (OX2R) agonist, produced dose-dependent reductions in attention-deficit hyperactivity disorder...
J&J’s Caplyta posts rapid Phase III benefit in bipolar mania
Johnson & Johnson's (NYSE: JNJ) lumateperone (Caplyta) produced a statistically significant reduction in manic symptoms in bipolar I disorder in a pivotal...
AbbVie partners with Iambic to apply AI platform across immunology, neuroscience, and oncology
AbbVie (NYSE: ABBV) and San Diego-based Iambic Therapeutics announced a multi-year collaboration to apply Iambic's AI-driven small molecule discovery...
Insmed’s Arikayce label expansion filing gets January 2027 PDUFA date
The US FDA has granted Priority Review to a supplemental New Drug Application (sNDA) from Bridgewater, New Jersey-based Insmed Incorporated (Nasdaq: INSM)...
Vironexis reports early durable ALL responses with one-time AAV therapy
Early Phase I/II data from San Diego-based Vironexis Biotherapeutics show that a single dose of an adeno-associated virus (AAV)-based gene therapy can...
LEO Pharma gains priority review for Tanabe-acquired oral therapy for rare porphyrias
The US FDA has accepted for filing and granted Priority Review to the New Drug Application (NDA) for dersimelagon, an investigational oral melanocortin 1...
Anaphylm returns to FDA after Aquestive addresses usability, PK concerns
New Jersey-based Aquestive Therapeutics, Inc. (Nasdaq: AQST) resubmitted its New Drug Application (NDA) to the US FDA for Anaphylm (dibutepinephrine)...
The AllSci Brief
Free, systematic R&D and deal news. Daily.